Senolytic

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

A senolytic (from the words “senescence” and “lytic” – destroying) is among the class of small molecules under basic research to determine if they can selectively induce death of senescent cells.[1] The goal of those working to develop senolytic agents is to delay, prevent, alleviate, or reverse age-related diseases.[2]. The opposite of senolytic is "senostatic" which means to suppress senescence.

Research[edit]

Multiple possible senolytic agents are under investigation.[3] Certain anti-cancer agents may in low doses decelerate aging and age-related diseases.[4] Targeting cancer prevention pathways with anti-cancer agents may confer longevity effects by offering protection from metabolic pathologies during aging, independently of effects on cancer.[5] Navitoclax, also known as ABT-263, was originally studied as an anti-cancer drug.[6]

See also[edit]

References[edit]

  1. ^ Childs BG, Durik M, Baker DJ, van Deursen JM (2015). "Cellular senescence in aging and age-related disease: from mechanisms to therapy". Nature Medicine. 21 (12): 1424–35. doi:10.1038/nm.4000. PMC 4748967. PMID 26646499.
  2. ^ Kirkland JL, Tchkonia T (2015). "Clinical strategies and animal models for developing senolytic agents". Experimental Gerontology. 68: 19–25. doi:10.1016/j.exger.2014.10.012. PMC 4412760. PMID 25446976. Retrieved 2015-12-28.
  3. ^ Baumann, Kim (2018-07-27). "Rejuvenating senolytics". Nature Reviews Molecular Cell Biology. 19 (9): 543. doi:10.1038/s41580-018-0047-5. ISSN 1471-0072. PMID 30054558.
  4. ^ Blagosklonny MV (2013). "Selective anti-cancer agents as anti-aging drugs". Cancer Biology & Therapy. 14 (12): 1092–7. doi:10.4161/cbt.27350. PMC 3912031. PMID 24345884.
  5. ^ Slack C, Alic N, Partridge L (2015). "Could cancer drugs provide ammunition against ageing?". Cell Cycle (Georgetown, Tex.). 15 (2): 153–5. doi:10.1080/15384101.2015.1118905. PMC 4825846. PMID 26587873.
  6. ^ Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW (2008). "Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models". Clinical Cancer Research. 14 (11): 3268–77. doi:10.1158/1078-0432.CCR-07-4622. PMID 18519752. Retrieved 2015-12-30.

External links[edit]